Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Samsung Bioepis Set To Join High-Concentration Humira Party In Canada

Health Canada Approval Follows Celltrion, JAMP Launches

Executive Summary

Samsung Bioepis has confirmed launch plans for its citrate-free, high-concentration Hadlima (adalimumab) biosimilar after it was waved through the Canadian healthcare regulator.

You may also be interested in...



Lower Than Expected Adalimumab Uptake Dampens Organon Outlook

Organon has reduced its full-year revenue expectations following a number of headwinds, including lower-than-expected uptake of its adalimumab biosimilar.

Organon: ‘Those $4bn-$5bn Biologics – That’s A Nice Place To Play In Biosimilars’

Joe Azzinaro, Organon’s global commercial leader for biosimilars, sat down to talk with Generics Bulletin about its commercialization expertise and investments for the future.

Alvotech And Teva File US Stelara Rival Ahead Of 2023 Expiry

Alvotech and marketing partner Teva have confirmed that their AVT04 proposed ustekinumab biosimilar rival to Stelara has been filed with the US FDA, ahead of a key patent expiry later this year.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel